Lilly is buying AtaiBeckley for $6.75 a share in cash, an aggregate equity value of about $2.8 billion, plus a contingent value right worth up to $2.50 a share, or roughly $1.0 billion more. The prize is BPL-003, an intranasal form of mebufotenin benzoate (synthetic 5-MeO-DMT) carrying FDA Breakthrough Therapy Designation and heading into Phase 3 for treatment-resistant depression. Big pharma has just bought a psychedelics company outright.

Read the CVR, not the headline. Sixty percent of it is a bet on federal drug policy.

The three CVR milestones are $1.00 a share if VLS-01 starts Phase 3 within four years, $0.50 if BPL-003 wins US approval and DEA rescheduling within five, and $1.00 if VLS-01 does the same within seven. Two of the three, $1.50 of the $2.50, do not pay on clinical success. They pay on the Drug Enforcement Administration moving a Schedule I molecule. That is not a development milestone, it is an access milestone, and Lilly has priced it at exactly zero on signing. An approved drug that stays Schedule I is a drug no one can prescribe. Lilly bought the science with cash and handed the scheduling risk back to selling shareholders. Watch this structure: it is the template every psychedelics takeout after this one will be measured against.

A Warburg Pincus-led group, reported to include the Abu Dhabi Investment Authority, agreed on 13 July to take control of PANTHERx Rare from Nautic Partners, General Atlantic and The Vistria Group. The official announcement disclosed no price. The Wall Street Journal put it above $7 billion including debt and Axios Pro confirmed roughly $7 billion, so treat the number as credible reporting rather than a disclosed term. The anchor that is documented: Centene’s SEC filing booked $1.373 billion of proceeds when it sold PANTHERx in 2022. Four years, better than five times the money.

Nobody bought a drug here. Somebody bought the only door those drugs fit through.

CVS, Cigna and Optum handle roughly two thirds of US specialty prescription revenue, and all three are welded to a pharmacy benefit manager. PANTHERx is the largest independent, and it sells itself as manufacturer-aligned rather than payer-aligned, which in a limited-distribution rare network is the entire product. The orphan market runs about $243 billion this year against a projected $687 billion by 2035. Warburg is not underwriting a molecule, it is underwriting the toll booth every one of those molecules has to pass, and it is the one booth a payer does not own. For manufacturers the question after close is not who won the auction, it is whether an independent under leverage stays independent.

AstraZeneca took exclusive worldwide rights to Zegfrovy (sunvozertinib), Dizal’s oral irreversible EGFR inhibitor, on 14 July. Terms: $600 million upfront, up to $900 million in milestones, tiered royalties reported up to low double digits. Zegfrovy is already approved in the US and China for EGFR exon 20 insertion NSCLC after platinum chemotherapy, did $83.4 million of 2025 revenue at plus 85 percent, and has positive Phase 3 WU-KONG28 data supporting a first-line filing already lodged with FDA and China’s CDE.

Forty percent committed on signing, against roughly six cents on the dollar for licensing across H1. Approved assets get cash. Hope gets milestones.

Two details the wire missed. First, the milestone breakout was disclosed: $400 million development, $500 million sales, in Dizal’s filing to the Shanghai Stock Exchange, in Chinese. Second, and better: Dizal is AstraZeneca’s own spinout. AZ formed it in 2017 as a JV with SDIC, handed over its China Commercial Innovation Center and three preclinical candidates, and the oncology one became Zegfrovy. AstraZeneca gave this molecule away nine years ago and just paid $600 million to get it back. That complicates the tidy China-originates story we have been telling all year. China did not originate this one. China developed it, to approval, faster than the parent would have.

Announced 14 July on the opening day of BIO Asia-Taiwan: Insilico pairs its Pharma.AI stack with Bora’s manufacturing and commercial infrastructure, potential value above $2.5 billion if fully implemented. Read that clause twice. The definitive agreements have not been negotiated or executed. There is no upfront to report because there is not yet a contract to pay one under. The strategy is real and genuinely new, pushing generative AI downstream from discovery into the factory, but the number is a press release.

Four framework deals in four months. This is not a pipeline, it is a business model.

Lilly in March at up to $2.75 billion, Takeda on 1 July at up to $600 million, Bora on 14 July at $2.5 billion, on top of the SK deal we covered in the 22-28 June issue. The headline totals are marketing; the upfronts are the revenue, and the revenue is working. Insilico guided H1 2026 to $102.5 to $106.5 million, up 273 to 287 percent, with net profit of $33.5 to $39.5 million, against $56.24 million for all of 2025. It now has 13 of the top 20 pharma as partners. Insilico has solved a problem most of the AI cohort has not: it is profitable. It got there by selling frameworks, not drugs. When you read $2.5 billion, ask what cleared, and this week ask whether anything was even signed.

DePuy Synthes bought Expanding Innovations on 16 July, a Mountain View maker of non-screw expandable interbody cages for spine, and said it will fold the X-PAC portfolio into its Velys robotic spine platform. Terms were not disclosed and on its own the deal is a bolt-on. The context is what makes it a signal.

Businesses being prepped for sale do not usually buy things. This one has bought twice since May.

J&J announced its intent to separate orthopaedics in October 2025, a $9.2 billion revenue business, targeting 18 to 24 months. By February 2026 Bloomberg had J&J running a sale process, with Bloomberg Intelligence valuing the unit near $20 billion, or $28 billion with debt, and several large PE firms weighing joint bids. In May, DePuy picked up Gemtrack radiofrequency tracking for navigation and robotics across joint reconstruction. Now spine robotics. Both purchases point at the same place, and both landed after J&J’s own CFO told the FT that the next phase of orthopedic innovation, robotics included, was “beyond our scope and probably in better hands somewhere else.” A parent that believed in this business would be building it, not narrating its exit while the unit shops. Read the bolt-ons for what they are: a seller staging the house. If PE writes a $20 billion check, it is buying a robotics story assembled in the ninety days before the auction.